Harvard Bioscience (HBIO) Cash & Equivalents (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash & Equivalents data on file, last reported at $7.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 27.98% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 27.98% YoY) and the FY2025 annual result came in at $8.6 million, up 109.69% from the prior year.
• Cash & Equivalents declined to $7.1 million in Q1 2026 per HBIO's latest filing, from $8.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $8.6 million in Q4 2025 and bottomed at $3.8 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $4.6 million (2024), against an average of $5.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 42.36%; it then surged 109.69% in 2025.
• Tracing HBIO's Cash & Equivalents over 5 years: stood at $4.5 million in 2022, then declined by 4.99% to $4.3 million in 2023, then slipped by 4.09% to $4.1 million in 2024, then surged by 109.69% to $8.6 million in 2025, then decreased by 17.6% to $7.1 million in 2026.
• Per Business Quant, the three latest HBIO Cash & Equivalents figures stand at $7.1 million (Q1 2026), $8.6 million (Q4 2025), and $6.8 million (Q3 2025).

Peer Comparison